RAC 3.03% $1.70 race oncology ltd

Ann: Zantrene AML trial in Israel advances to Phase 2, page-123

  1. 8,500 Posts.
    lightbulb Created with Sketch. 1393
    Why would the FDA amend the 505(b)(2) pathway just for RAC?
    Sheba 2 is a combo trial, so it isn't on a pathway using the historical single agent results.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.